Graham Holdings Company (GHC) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with GHC. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Graham trades at a market value roughly in line with its trailing revenue (about 1 times sales) and about 1.1 times book value, consistent with its conglomerate, sum-of-the-parts profile rather than a high-growth multiple. Headline EPS is distorted by mark-to-market movements on its investment portfolio and one-off items, which is why the trailing P/E near 10 sits far below the forward P/E near 18. The very small share count (roughly 4.2 million shares implied by price and market cap) means per-share figures and buybacks carry outsized weight.

For the fiscal year ending Dec 2026, the one analyst publishing estimates on GHC expects earnings of $69.00 per share (+34% on the year before) and revenue of $5.2 billion (+6.0%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Graham Holdings Company next reports around October 28, 2026 (an estimated date), which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering GHC do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $67.00 per share, -2.9% on the fiscal year ending Dec 2026 estimate of $69.00. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of October 2026, GHC trades at about 9.7 times trailing earnings and 18.0 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year, which is worth understanding before assuming a long-horizon rise.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Graham Holdings Company can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Education (Kaplan) as the core engine, Healthcare (CSI Pharmacy) expansion, Capital allocation and sum-of-the-parts value. The risk cited most often against it is reported earnings are lumpy because they include unrealized gains and losses on the equity portfolio and periodic impairment charges, which can obscure underlying operating trends.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the GHC is it a buy page. This page deliberately stops at the numbers.